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Abstract Chemokine receptors belong to the class of G
protein-coupled receptors and are important in the host defense
against infections and inflammation. However, aberrant che-
mokine signaling is linked to different disorders such as cancer,
central nervous system and immune disorders, and viral infec-
tions [Scholten DJ et al. (2012) Br J Pharmacol 165(6):1617–
1643]. Modulating the chemokine receptor function provides
new ways of targeting specific diseases. Therefore, discovery
and development of drugs targeting chemokine receptors have
received considerable attention from the pharmaceutical indus-
try in the past decade. Along with that, the determination of
bioactivities of individual metabolites derived from lead com-
pounds towards chemokine receptors is crucial for drug selec-
tivity, pharmacodynamics, and potential toxicity issues. There-
fore, advanced analytical methodologies are in high demand.
This study is aimed at the optimization of a new analytical
method for metabolic profiling with parallel bioaffinity assess-
ment of CXCR3 ligands of the azaquinazolinone and
piperazinyl-piperidine class and their metabolites. The method
is based on mass spectrometric (MS) identification after liquid
chromatographic (LC) separation of metabolic mixtures. The
bioaffinity assessment is performed Bat-line^ via high-
resolution nanofractionation onto 96-well plates allowing direct
integration of radioligand binding assays. This new method
enables identification ofmetabolites from lead compounds with
associated estimation of their individual bioaffinity. Moreover,
the identification of the metabolite structures via accurate mass
measurements and MS2 allows the identification of liable met-
abolic Bhotspots^ for further lead optimization. The efficient
combination of chemokine receptor ligand binding assays with
analytical techniques, involving nanofractionation as linking
technology, allows implementation of comprehensive metabol-
ic profiling in an early phase of the drug discovery process.
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Introduction
In general, the majority of drugs undergo in vivo metabolism
to more polar products leading to improved clearance by the
kidney. During this biotransformation process, even subtle
changes in the structure may lead to changes in the bioactivity
at and/or affinity for the drug target. Moreover, the selectivity
and functional activity of these metabolites can be seriously
compromised compared to the parent compound. This may
influence the therapeutic effect of the drug and, as a conse-
quence, prevent a lead compound from being developed fur-
ther. In that respect, determination of the bioactivity of indi-
vidual metabolites derived from lead candidates is crucial for
profiling the eventual pharmacodynamics of the drug and
highlighting potential toxicity issues. These studies are
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usually restricted to only a few lead candidates and postponed
until a later stage of drug development since currently used
analytical methods are laborious and costly and do not allow
bioactivity assessment of metabolites, but only their identifi-
cation. However, metabolic profiling of a lead candidate in an
early stage of the drug discovery process is highly desirable as
attrition costs increase when drug candidates progress through
the drug discovery and development stages [2].
Recently, a new analytical strategy that allows characteri-
zation of bioactive metabolites from G protein-coupled recep-
tor (GPCR) ligands at an early stage of lead optimization [3]
was introduced. In this regard, bioactivity is referring to the
interaction of such a metabolite with the receptor displayed as,
e.g., receptor binding affinity and/or receptor (in)activation. In
a parallel study, the histamine H4 receptor was considered the
drug target while metabolite binding to the histamine H3 re-
ceptor was incorporated to assess selectivity loss by off-target
binding to the H3 receptor [4]. The analytical technology is
based on mass spectrometric (MS) identification of individual
metabolites after liquid chromatographic (LC) separation of
metabolic mixtures. The parallel assessment of bioactivity is
performed at-line via high-resolution nanofractionation onto
high-density microtiter plates followed by performing either
receptor binding or functional assays [3, 4]. Since the high-
resolution nanofractionation collects fractions in the second
range, the eventual bioactivities measured from the wells can
be reconstructed into bioactivity chromatograms with suffi-
cient resolution to allow accurate correlation of bioactivity to
individual metabolites. To this end, the peak shapes and reten-
tion times from the reconstructed bioactivity chromatograms
are compared with the LC-MS data from which the bioactives
are identified.
This study is aimed at the optimization of a new analytical
method for bioaffinity assessment of mixtures of small mole-
cule ligands binding the CXCR3 receptor, such as metabolic
mixtures. CXCR3 is a member of the chemokine receptor
family that binds chemokines, which are small proteins rang-
ing between 8 and 12 kDa, as their endogenous ligands [5].
Chemokine receptors in turn belong to the superfamily of G
protein-coupled receptors (GPCRs). GPCRs are 7-
transmembrane spanning receptor proteins that play a key role
in different physiological and pathological conditions and
have demonstrated to be valid drug targets. The chemokine
receptor CXCR3, for example, is a potential drug target for
several immune-related diseases, such as allograft rejection
[6], atherosclerosis [7], psoriasis [8], multiple sclerosis [9,
10], rheumatoid arthritis [11], and type I diabetes [12] where
aberrant CXCR3 and ligand expression seems to be a com-
mon denominator [13, 14]. Moreover, antagonism of CXCR3
in animal models of disease showed beneficial effects in re-
duction of allograft rejection in organ transplantation as well
as attenuation of atherosclerotic plaques and metastasis of
certain tumors [15–19]. As such, development of small
molecule drugs targeting the CXCR3 receptor attracted the
interest of the pharmaceutical industry and academia. Their
efforts have led to the discovery and development of high-
affinity small molecule ligands for the CXCR3 receptor by
high-throughput screening of libraries of compounds and nat-
ural products [13, 14]. The different classes of CXCR3 ligands
have been reviewed [14]. One well-studied class of com-
pounds is the (aza)quinazolinone class [13, 14], which in-
cludes AMG487 [20], one of the early CXCR3 antagonists
that showed therapeutic potential. It even entered clinical trials
for treatment of psoriasis and progressed to phase II, yet it was
discontinued due to lack of efficacy. It has been suggested that
this clinical failure is caused by non-linear pharmacokinetics
due to inhibition of cytochrome P450 enzymes (CYP3A)
resulting in variable drug exposure [21, 22]. Another well-
studied compound from this class is NBI-74330 [23], which
has higher affinity than AMG487 and also shows therapeutic
potential in an animal model of atherosclerosis [18].
The piperazinyl-piperidine class of compounds represents
another distinct chemical class containing high-affinity allo-
steric CXCR3 antagonists [24–28]. Interestingly, a compound
from this class (SCH-546738) shows activity in several animal
models of disease, including allograft rejection and rheuma-
toid arthritis [19].
In this study, the analytical method presented combining
LC-MS analysis and parallel at-line nanofractionation with
subsequent bioaffinity assessment was optimized and validat-
ed for analysis of mixtures targeting the CXCR3 chemokine
receptor. Furthermore, the optimized method was applied to
the metabolic profiling and the bioaffinity assessment of me-
tabolites of two high-affinity small molecule CXCR3 antago-
nists: NBI-74330 from the azaquinazolinone class [29, 30]
and VUF11211 from the piperazinyl-piperidine class [28]
(see Fig. 1a for their structures). Both compound classes bind
to CXCR3 in an allosteric fashion, having distinct yet partially
overlapping binding sites in its transmembrane region [25,
28]. Metabolites were separated using reversed phase liquid
chromatography (LC) followed, in parallel, by high-resolution
nanofractionation onto 96-well plates to assess the bioaffinity
of parent compounds and metabolites and accurate mass MS
and MS2 analysis for structural identification of formed me-
tabolites. The bioaffinity was assessed using a radioligand
binding assay employing the recently described small mole-
cule radioligand [3H]-VUF11211 [31]. In total, ten metabo-
lites of NBI-74330 and eight metabolites of VUF11211 have
been identified and their structures were partially or fully elu-
cidated. One metabolite of NBI-74330 and two metabolites of
VUF11211 were identified as the bioactive metabolites. The
active metabolite of NBI-74330 has been already described
previously as a pyridyl N-oxide in the study conducted by
Jopling et al. [32], and its structure and the bioactivity were
confirmed in this study. However, no other information about
the metabolites of NBI-74330 have been published
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previously. The metabolism of the VUF11211 compound has
not been studied before and the data reported in this study
represents the first data known about VUF11211 metabolites
so far. Considering the results obtained, this study shows that
the efficient combination of receptor ligand binding assays
with analytical techniques involving nanofractionation of me-
tabolites is of importance for the implementation of compre-
hensive metabolic profiling in an early phase of the drug dis-
covery process.
Material and methods
Chemicals, reagents, and materials
All the salts used for buffer preparation were of analytical
grade and purchased from standard suppliers (Merck, Fluka
or Sigma-Aldrich). Cell culture material was obtained from
PAA Laboratories GmbH (Pasching, Austria). Glucose-6-
phosphate and glucose-6-phosphate-dehydrogenase were pur-
chased from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Acetonitrile (ACN; LC-MS grade) was purchased from
Biosolve B.V. (Valkenswaard, The Netherlands). Magnesium
chloride hexahydrate was purchased fromFluka (Zwijndrecht,
The Netherlands). Formic acid (FA) was purchased from
Merck (Zwijndrecht, The Netherlands). Nicotinamide adenine
dinucleotide phosphate (NADPH) tetra sodium salt was
obtained fromApplichem (Lokeren, Belgium). G418was pur-
chased from Duchefa (Haarlem, The Netherlands). 125I-
CXCL10, [3H]-VUF11211 (38.4 Ci/mmol) [31], and
Whatman GF/C filter plates were purchased from Perkin
Elmer (Groningen, The Netherlands).
VUF11211 was synthesized in enantiopure form in our labs
according to the general synthetic procedures patented by
Merck [33]. The synthesis of NBI-74330 has been described
before [29]. Stock solutions of the ligands were prepared in
DMSO (20 mM) and stored at −20 °C.
HEK293 cells stably expressing human CXCR3 receptor
(HEK293/CXCR3) were a gift from Dr. K. Biber, University
Medical Center Groningen, The Netherlands.
Liquid chromatography with high-resolution at-line
nanofractionation
L i qu i d ch r oma t o g r a phy w i t h h i g h - r e s o l u t i o n
nanofractionation was done in similar fashion as by a recent
publication [4]. Briefly, the gradient LC system consisted of a
Gilson International (Den Haag, the Netherlands) model 234
autoinjector with a 100-μL loop, a Shimadzu (‘s
Hertogenbosch, the Netherlands) LC-20 AD binary pump,
and a Shimadzu SPD-20A UV-Vis detector set to 254 nm.
The chromatographic column used was a Waters (Milford,
MA, USA) xBridge C18 column (4.6 mm×100 mm; 5 μm)











































Fig. 1 a Chemical structures of two CXCR3 antagonists: I NBI-74330
from the (aza)quinazolinone class II VUF11211 from the piperazinyl-
piperidine class. b Schematic overview of the analytical setup. I Separa-
tion and UV detection of the metabolic mixtures is followed by high-
resolution nanofractionation for bioaffinity screening in radioligand bind-
ing assay. II Separation on LC-UV system is followed by accurate MS
and MS2 measurements for (partial) structure identification of the metab-
olites present in the mixture
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3.5 μm). The LC column was thermostated by a Jones Chro-
matography (Lakewood, CO, USA) 7971 Column Heater set
at 30 °C. The flow rate was 0.6 mL/min. The mobile phase A
contained 98%H2O, 2%ACN, and 0.1% FA, and the mobile
phase B contained 2 % H2O, 98 % ACN, and 0.1 % FA. For
bioassay optimization, the following gradient was used: 3 min
at 0 % B, a linear gradient to 90 % B in 10 min, and 5 min at
90 %. Re-equilibration to starting conditions occurred in
1 min followed by a 4 min isocratic operation. The gradient
used for the analysis of metabolic mixtures of NBI-74330
was: 0–3 min at 0 % B, linear gradient to 20 % B in 20 min,
10 min at 20 % B, re-equilibration to 0 % B in 1 min followed
by 6 min isocratic separation. Metabolic mixtures of
VUF11211 were analyzed starting with 3 min isocratic sepa-
ration at 25 % followed by 20 min linear gradient to 45 % B
and 10 min isocratic separation at 45 % B. Returning to the
starting conditions was done in 1 min and followed by 6 min
re-equilibration. Nanofractionation of relevant sections of the
chromatograms (range where the metabolites and parent elut-
ed) was done directly after the post-column UV detection.
Liquid chromatography-mass spectrometry
LC-MS analysis of metabolic mixtures was performed using a
Shimadzu LCMS ion-trap–time-of-flight hybrid (IT-TOF)
system equipped with an electrospray ionization (ESI) source.
The injection volume was 50 μL. The separation was per-
formed using the same columns, solvent, and gradient condi-
tions as described above. All MS measurements were per-
formed in positive-ion mode. The instrument settings were:
4.5 kV spray voltage, 125 °C source heating block and curved
desolvation line temperature, 70 kPa drying gas pressure, and
1.5 L/min nebulizing gas flow. The scan range was set be-
tween m/z 200 and 1200 with a 10-ms ion accumulation time
in MS2 data-dependent mode. For CID, the collision energy
was set to 90–110 % and collision gas to 50 % at 45 kHz.
Shimadzu LCMS Solutions software was used for data acqui-
sition and processing. A Shimadzu SPD-20A UV detector
(254 nm) was placed in series prior to the MS for additional
data collection on the metabolites (data not used) and for pos-
sible transfer to subsequent LC-UVanalysis.
Metabolic incubations
A modified protocol described by Reinen et al. [34] was used
for microsomal incubations. Pig liver microsomes (∼20 mg/
mL protein) were diluted 1:10 in incubation buffer (50 mM
KH2PO4 buffer pH 7.4, 5 mMMgCl2, 5 mM glucose-6-phos-
phate, and 5 activity units/mL glucose-6-phosphate dehydro-
genase) at 4 °C. Ligands were added at room temperature to a
final concentration of 100 μM (from 20 mM DMSO stocks).
Directly before the start of the incubations, a freshly prepared
solution of 30 mM NADPH in 50 mM KH2PO4 buffer was
added at 37 °C in an amount to obtain a 10% [v/v] share of the
total incubation volumes. The same volume of 10 mMNADP
Hwas added to the incubations 30 and 60min after the start of
the incubations. The incubations were stopped after 90 min
with 200 % incubation volume of ice-cold acetonitrile. Sub-
sequently, the formed protein precipitates were centrifuged for
5 min at 11.200g. Next, the supernatants were transferred to
new Eppendorf tubes for solvent evaporation in a Savant
(Holbrook, NY, USA) SpeedVac Plus SC110A. The samples
were stored at −20 °C prior to use and re-dissolved in eluent A
so that the concentration corresponded to 100 μM of the par-
ent compound prior to incubation.
Cell culture
A HEK293/CXCR3 cell line was cultured in Dulbecco’s
Modified Eagles Medium with high glucose concentration
(4.5 g/L) supplemented with 10 % fetal bovine serum, 1 %
penicillin/streptomycin, and 400 μg/L G418 at 37 °C in 5 %
CO2.
Membrane preparation
The HEK293/CXCR3 crude membrane extracts were pre-
pared as previously described by Verzijl et al. [30]. Briefly,
HEK293/CXCR3 cells were washed twice with ice-cold PBS
and centrifuged 10 min at 1500g. The cell pellets were resus-
pended in ice-cold membrane buffer (15 mM Tris-HCl,
0.3 mM EDTA, and 2 mMMgCl2 at pH 7.4 and 4 °C). After
homogenization using a 15-mLTeflon glass homogenizer and
rotor, two freeze/thaw cycles were performed. The homoge-
nate was then centrifuged at 40.000g for 25 min at 4 °C. The
supernatant was carefully removed, and the pellet was resus-
pended in ice-cold Tris-sucrose buffer (20 mM Tris, 250 mM
sucrose at pH 7.4 and 4 °C). The membrane preparation was
frozen in liquid nitrogen and stored at −80 °C. The protein
concentration was determined using the BCA Protein Assay
Kit (Thermo Scientific, Rockford, IL, U.S.A) according to the
manufacturer’s instructions.
Radioligand displacement binding assay
For optimization of the radioligand binding assay, a standard
mixture of NBI-74330 and VUF11211 (both at 20 μM con-
centrations) was separated using the LC conditions described
above, and collected onto 96-well plates. On every 96-well
plate used for fractionation, two or three rows of outer wells
were used to construct IC50 curves with internal controls for
assessment of maximum and minimum signal in the particular
assay. For this, a serial dilution of NBI-74330was used. Seven
different concentrations of NBI-74330 ranging from 10 pM to
10 μMwere pipetted in duplicate or triplicate on each 96-well
plate after nanofractionation of an analysis mixture and prior
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to freeze-drying. The last wells in the control rows contained
eluent A prior to freeze-drying. After the plates were
bioassayed and the bioactivity chromatograms were plotted,
a corresponding IC50 curve of NBI-74330was plotted for each
96-well plate from the serial dilution results as a validation of
a successful bioassay plate analysis. Subsequently, for each
trace, the Z′ factor was calculated as follows:
Z






where the σc refers to the standard deviation of the
controls and μ refers to the mean of the controls. A
value Z′ <0.5 is considered to be an assay with low
quality, whereas 1>Z′≥0.5 is considered to be an excel-
lent assay, and Z′=1 the ideal assay [35]. In our setup,
the positive controls (c+) were the wells containing 10 μM
NBI-74330, which provided full displacement of the
radioligand used. The negative controls (c−) were the wells
that contained eluent A prior to freeze-drying. For the outline
of the 96-well plates used in this study, please refer to Fig. S1
in the Electronic Supplementary Material (ESM).
The radioligand binding assay was performed in a similar
fashion as described previously by Scholten et al. [31]. Short-
ly, the [3H]-VUF11211 radioligand was dissolved in binding
buffer (50 mM Tris-HCl buffer pH 7.4 at room temperature,
100 mM NaCl, 0.1 % Tween 80, and 0.1 % BSA) and added
to wells containing ligand or collected high-resolution frac-
tions of the ligands. These fractions contained the incubated
ligands and/or their metabolites freeze-dried directly on the
plate. Subsequently, a suspension of HEK293/CXCR3 mem-
brane extract (7.9 pmol CXCR3 receptor/mg protein) in bind-
ing buffer was added to each well, such that the final concen-
tration of protein was approximately 8 μg/well, which
corresponded to 63 fmol of CXCR3 receptor [31]. The final
concentration of the radioligand in the wells was approximate-
ly 2 nM, and the total assay volume was 100 μl/well. After 2 h
incubation at room temperature, the membranes were collect-
ed on Whatman GF/C filter plates pretreated with 0.5 % (w/v)
BSA in H2O and rapidly washed three times with ice-cold
wash buffer (50 mM Tris-HCl buffer pH 7.4 at 4 °C,
500 mM NaCl) to remove unbound radioligand. Next, the
plates were dried for 30 min at 55 °C followed by addition
of 25 μL/well scintillation liquid with a multidrop (Thermo
Fisher, Breda, The Netherlands). A PerkinElmer 1450
MicroBeta scintillation counter was used to record the radio-
activity on the GF/C plates.
The 125I-CXCL10 displacement assay was done in the
same fashion. The radioligand was diluted in binding buffer
(50 mM HEPES buffer pH 7.4 at room temperature, 500 mM
NaCl, 5 mMMgCl2, and 1 mM CaCl2) to the final concentra-
tion of approximately 100 pM. The final concentration of the
membrane suspension was 15 μg/well. The GF/C plates were
pretreated with 0.5 % (w/v) PEI in H2O and rapidly washed
three times with ice-cold wash buffer (50 mM Tris-HCl buffer
pH 7.4, 500 mM NaCl, 5 mM MgCl2, and 1 mM CaCl2).
Results
Nanofractionation and assay optimization
An analytical method was developed for structure identifica-
tion and bioaffinity profiling of metabolic mixtures for the
CXCR3 lead compounds NBI-74330 and VUF11211 using
the approach depicted in Fig. 1b. A standard mixture of these
two small-molecule CXCR3 ligands (20 μM) was used for
method optimization and validation. Subsequently, this opti-
mized method was applied to the analysis of metabolic mix-
tures of these two compounds. These two compounds belong-
ing to different chemical classes were chosen for the optimi-
zation of the method considering that the approach developed
was optimized with respect to the radioligand binding assay.
In general, the LC gradient has to be adjusted to each analysis
mixture to obtain satisfying separation of the compounds pres-
ent in the mixture.
Radioligand concentration and membrane amounts
The method was first optimized for the concentration of [3H]-
VUF11211 radioligand, the amount of used membranes ex-
pressing the CXCR3 receptor, and the nanofractionation res-
olution after LC separation. The optimal radioligand concen-
tration was selected to be 2 nM per well based on the initial
results of the Kd determination that was performed for the
radioligand characterization [31]. Subsequently, the method
was optimized for the amount of membranes expressing
CXCR3 that was used per well of the bioassay microtiter
plate. A concentration series of membrane preparations (16,
8, 4, and 2 μg/well) was tested in duplicate, and the results are
shown in Fig. 2a (12 s/well nanofractionation resolution). A
bioaffinity peak was defined as a decrease in signal more than
three times the standard deviation of the average baseline and
should consist of more than two data points. The peaks from
the bioaffinity traces corresponded to the LC-UV trace
(Fig. 2a trace V) and were matched to either VUF11211 or
NBI-74330. The identity of compounds was confirmed by
using accurate mass measurements obtained with high-
resolution MS. The two peaks observed for every
superimposed chromatogram in Fig. 2a correspond to the
two compounds in the standard mixture and are easily detect-
ed in all four bioaffinity traces. For all conditions, the Z′ factor
was calculated, which is a statistical measure of effect size
taking intra-experimental variability into account. The mem-
brane concentration of 8 μg/well was selected for further ex-
periments as it displayed the highest Z′ factor 0.60, suggesting
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that it is an excellent assay in terms of baseline separation and
intra-assay variability (Fig. 2a).
Resolution of nanofractionation
The next step in the method development was the optimiza-
tion of fractionation resolution, which determines the quality
of correlation between the chromatographic separation and
bioassay readout. Higher nanofractionation frequencies yield
more assay points per separated peak, thereby providing better
resolution capabilities. This comes with the compromise of
sensitivity as separated compounds are fractionated over more
wells and are thus more diluted in the bioassay. Nanofractions
of the standard mixture were collected in two relatively low
(24 and 12 s/well) and two high (6 and 3 s/well) resolution.
The resulting bioaffinity chromatograms are shown in dupli-
cate in Fig. 2b. Detection of clear bioaffinity peaks with their
accurate correlation to chromatography peaks was not reliably
done with 24 s/well fractionations (trace I) due to the low
number of assay points describing each peak in combination
with relatively high baseline fluctuations (large standard devi-
ation). On the other hand, 3 s/well fractions (trace IV) result in
a large number of assay points describing the bioaffinity chro-
matogram, but at the cost of more diluted fractions, and the
inability of collecting a full chromatogram on one 96-well
plate, thereby introducing potential interplate differences.
The 6 s/well (trace III) and 12 s/well (trace II) fractions pro-
duced good resolution and the ability to be performed on one
96-well plate. The 6 s/well fractions resulted in the most op-
timal assay conditions in terms of the Z' factor (0.66). The
overall optimal bioassay conditions were found to be: 2 nM
radioligand concentration, 8 μg/well protein concentration in
crude membrane suspension, and a nanofractionation frequen-
cy of 6 s/well.
Evaluation and validation
Next, in order to evaluate and validate the method with
respect to detection sensitivity, the bioaffinity assay was
calibrated by using a range of different concentrations of
the two compounds in the mixture (1 nM to 200 μM).
The results obtained are shown in Fig. 3. The peaks have
narrow shapes upon analysis of lower concentrations
(traces I–V), while they become broader with flattened
tops when higher concentrations of compounds are ana-
lyzed (traces VI–VIII). This is inherent to the nature of
the bioaffinity response: ligand binding displays a satura-
tion kinetics, which, when represented in log M scale,
gives a sigmoidal concentration response curve. This im-
plies that at a certain injected concentration, a full dis-
placement of radioligand is attained, resulting in a peak
maximum. Increasing the compound concentration beyond
this point only leads to peak broadening as maximum
displacement will also be attained in surrounding wells.
The bioaffinity traces with increasing peak maxima corre-
spond to the dose-dependent increases in binding of the
compounds to the receptor. Concentrations outside this
range give either no signal (low concentrations) or maxi-
mal signal (high concentrations). In other words,
radioligand binding assay represents a bioaffinity detector
capable to distinct different concentrations within its linear
dynamic range. This is comparable to other detectors, such
as MS and UV detectors used in this study. Both MS and
UV detectors give sharp peaks within their linear dynamic
range, while they cannot make a clear distinction between
concentrations that fall outside of this range. The differ-
ences in peak narrowness observed for the same concen-
tration of compounds analyzed with different detectors are
result of a different sensitivity of these detectors. Thus, the
observed peak broadening effects in the bioaffinity trace,
which are to some extent also present in the MS, but not
observed in the UV chromatogram, come from different
sensitivities of the detectors used. This becomes more ev-
ident when the limits of detection (LODs) for the two
compounds measured with the different detectors used in
this study are compared. The LODs fall within low mi-
cromolar range for the UV detection (approximately 4 μM
for both compounds tested) and in the low nanomolar
range for MS (approximately 15 nM injection for both
compounds tested) and bioaffinity (approximately 6 nM
for NBI-74330 and 1 nM for VUF11211) detection.
Fig. 2 Nanofractionation and assay optimization. a The optimization of
the concentration of the membrane preparation. Fractions were collected
in 12 s/well resolution after 100 μL injection and separation of mixture of
NBI-74330 and VUF11211 with 20 μM end concentration per
compound. Traces I–IV are reconstructed bioaffinity chromatograms
from the radioligand binding assay for CXCR3 receptor binding. UV
chromatogram trace (V) obtained after injection of 200 μM is given for
the correlation with the identity of the compounds. Bioaffinity traces
correspond to bioaffinity chromatograms obtained when final
concentrations of proteins in the membrane preparation were: 16 μg/
well (I), 8 μg/well (II), 4 μg/well (III), and 2 μg/well (IV), respectively.
The end concentration of 3H-VUF11211 radioligand was 2 nM. All
bioaffinity chromatograms are scaled equally and shown as an average
of a duplicate measurement, where the error bars reflect the variation
between the two separate measurements. b The optimization of the
nanofractionation resolution. Fractions were collected after 100 μL
injection and separation of mixture of NBI-74330 and VUF11211 with
20 μM end concentration per compound. Traces I–IV are bioaffinity
chromatograms from the radioligand binding assay for CXCR3 receptor
binding when four different nanofractionation resolutions were applied.
UV chromatogram trace (V) obtained after injection of 200 μM is given
for the correlation with the identity of the compounds. Traces I–IV
correspond to bioaffinity chromatograms obtained with 24, 12, 6, and
3 s/well nanofractionation resolution, respectively. The end
concentration of the membrane preparation was 8 μg/well and [3H]-
VUF11211 radioligand concentration was 2 nM. All bioaffinity
chromatograms are scaled equally and shown as an average of a
duplicate measurement, where the error bars reflect the variation
between the two separate measurements
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Results presented in Fig. 3 clearly show the suitability of
the developed approach for bioaffinity screening of the small
molecule ligands after LC separation and nanofractionation.
The LOD for both compounds are in the nanomolar range, as
can be seen in Fig. 3, which is in agreement with the affinities
of these compounds determined in the conventional [3H]-
VUF11211 binding assay (pKd=9.1±0.0 for VUF11211 and
pKi=8.4±0.0 for NBI-74330) as depicted in Fig. 4a (data
reproduced from Scholten et al. (32)). Similar nanomolar af-
finities were also measured in a conventional radioligand
binding assay where the ligands were subjected to freeze-
drying and reconstitution in assay buffer (data not shown).
Using the peak height from the bioassay (Fig. 3), concentra-
tion response curves were constructed (Fig. 4b), yielding sim-
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Fig. 3 Calibration of the
radioligand binding assay. Traces
I–VIII correspond to bioaffinity
chromatograms obtained after
injecting the series of dilutions of
the mixture of the two lead
compounds (NBI-74330 and
VUF11211). The injected
concentrations were 1.28, 6.24,
32, 160, and 800 nM and 4, 20,
and 200 μM, respectively. All
bioaffinity chromatograms are
shown as an average of a
duplicate measurement.
Nanofractionation resolution was
6 s. The end concentration of the
CXCR3 membrane preparation
was 8 μg/well and [3H]-
VUF11211 radioligand
concentration was 2 nM. UV
chromatogram trace (IX) obtained
after injection of 200 μM is given
in black for the correlation with
the identity of the compounds. All
bioaffinity chromatograms are
scaled equally and shown as an
average of a duplicate
measurement, where the error
bars reflect the variation between
the two separate measurements
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In the abovementioned bioassay setup, a small molecule
allosteric radioligand [3H]-VUF11211 was used, which binds
to the transmembrane domains of CXCR3 [28]. The CXCR3
chemokine CXCL10, the orthosteric ligand, did not produce
any displacement of [3H]-VUF11211 (not shown) as expected
based on results found earlier [31]. To check whether chemo-
kine proteins are compatible with the assay procedure (freeze-
drying and fractionation), a control experiment was carried out
using 125I-CXCL10 as radioligand and CXCL10 as competi-
tor. Using this approach, CXCL10 was injected and
nanofractionated for assessment of receptor binding after
HPLC separation. The nanofractionated CXCL10 was still
able to displace the orthosteric chemokine 125I-CXCL10
(Fig. 5), suggesting this approach could potentially be extend-
ed to studying proteins.
Metabolic profiling
The validation of the analytical method was proceeded with
the metabolic profiling of the two lead compounds NBI-
74330 and VUF11211. After in vitro preparation of the met-
abolic mixtures, the workup procedure involved reconstitution
of metabolic mixtures in eluent A after protein precipitation
and evaporation. All the measurements have been done in
duplicate using optimized method. The metabolic profiles of
NBI-74330 and VUF11211 are shown in Figs. 6 and 7, re-
spectively. The bottom part of both figures represents extract-
ed ion chromatograms (XICs) of parent compound and
formed metabolites (metabolite number annotation, with
corresponding m/z values presented in Tables 1 and 2). The
upper part of the figures shows reconstructed bioaffinity












































































Fig. 4 a Concentration response curves of NBI-74330 and VUF11211
measured in conventional radioligand binding assay. Binding
experiments were performed with approximately 1nM [3H]-VUF11211
and increasing concentrations of NBI-74330 (open circles) and
VUF11211 (filled circles). Data are presented as percentage of specific
binding. Obtained pKi values were 8.4±0.0 for NBI-74330 and 9.1±0.0
for VUF11211. b Concentration response curves of NBI-74330 and
VUF11211 constructed from the data obtained during the calibration of
the developed method. Each point represents the percentage of [3H]-
VUF11211 specific binding for each injected concentration of NBI-
74330 (open circles) and VUF11211 (filled circles). The specific
binding is defined as the corresponding peak height in the bioaffinity
chromatogram. Obtained pKi values were 7.9±0.1 for NBI-74330 and
9.3±0.1 for VUF11211
Time (min)






Fig. 5 Analysis of a CXCR3 endogenous ligand, CXCL10 chemokine. I
Bioaffinity chromatograms after LC separation and nanofractionation
after duplicate injections of 10 μM CXCL10 solution in water.
Fractions were collected in 6 s resolution. The end concentration of the
membrane preparation was 10 μg/well and 125I-CXCL10 radioligand
concentration was 125 pM. The bioaffinity chromatogram is shown as
an average of a duplicate measurement. II LC-MS trace depicted as
extracted ion current (XIC) of CXCL10 after 10 μM solution injection.
Correlation between structure identity and bioaffinity is enabled by the
parallel bioaffinity and MS analysis
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chromatograms of two different dilutions of the metabolic
mixtures injected. As with the parent compounds, the negative
peaks reflect binding to CXCR3 measured in the radioligand
binding assay. Correlation between structure identity and
bioaffinity is enabled by the parallel bioaffinity and MS anal-
ysis. Identification of metabolites is based on shifts in accurate
mass of parent and formed metabolites and of their fragments
in MS2. Chemical structures of NBI-74330 and VUF11211
showing their fragmentation patterns in MS2 are inserted in
Figs. 6 and 7, respectively. Tabulated information on the struc-
ture elucidation of the metabolites formed from NBI-74330
and VUF11211 is given in Tables 1 and 2, respectively.
Metabolic profiling of lead compound NBI-74330
Two peaks were observed in the bioaffinity chromatogram of
the metabolic mixture of NBI-74330 (Fig. 6(I and II)). These
peaks corresponded to the parent compound andMetabolite 3.
In total, ten metabolites were detected in the metabolic mix-
ture of NBI-74330 (Fig. 6(III)). Five primary metabolites
were: Metabolites 1, 2, and 3, which had a shift of m/z +16
indicating oxidation in the molecule, Metabolite 4, which had
a shift ofm/z –28 indicatingO-deethylation of the phenol ring,
andMetabolite 10, which had a shift ofm/z –91 pointing toN-
dealkylation of the amide (removal of methylpyridyl). Sec-
ondary metabolism products, Metabolites 5–9, all had a shift
of m/z –12, which indicated that O-dealkylation (loss of the
ethyl group in the phenol ring) in combination with an oxida-
tion. The structures of Metabolite 3, 4, and 10 could be
completely elucidated, while for the other metabolites only
partial identification was achieved. The single-charge precur-
sor ion [M+H]+ of NBI-74330 with m/z 606.212 gives three
major fragments in MS2 mode: ions with m/z 135.093,
268.108, and 402.193. The proposed structures of these
20µM
100µM






































Fig. 6 Analysis of a metabolic mixture of NBI-74330, a small molecule
ligand towards the CXCR3 receptor. Chemical structure of the parent
compound with the MS2 fragmentation scheme is inserted in the figure.
I and II Reconstructed bioaffinity chromatograms after LC separation and
nanofractionation of the metabolic mixture after duplicate injections at
two different concentrations corresponding to 20 and 100 μM pre-
incubation concentration of the parent compound. III LC-MS traces
depicted as extracted ion currents (XICs) of parent compound (black
trace) and formed metabolites (color coded notation). Correlation
between structure identity and bioaffinity is enabled by the parallel
bioaffinity and MS analysis. All bioaffinity chromatograms are scaled
equally and shown as an average of a duplicate measurement, where
the error bars reflect the variation between the two separate measurements
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Table 1 Interpretation of the MS
and MS2 results for NBI-74330
and its metabolites M1-M10. F1-
F3 are characteristic fragments
seen inMS2 spectra as depicted in
Fig. 6. A–E represent different











Compound Δ Δ Δ Δ
Parent = = = = Parent compound, NBI-74330
M1 +16 +16 +16 = +O in ABC
M2 +16 +16 +16 = +O in ABC
M3 +16 +16 = +16 +O in D
M4 −28 −28 −28 = O-dealkylation (change in A)
M5 −28; +16 −28 −28 O-dealkylation, +O in E
M6 −28; +16 −12 −12 O-dealkylation, +O in ABC
M7 −28; +16 −12 −12 = O-dealkylation, +O in ABC
M8 −28; +16 −12 −12 = O-dealkylation, +O in ABC
M9 −28; +16 −12 O-dealkylation, +O in ABC













































Fig. 7 Analysis of a metabolic mixture of VUF11211, a small molecule
ligand towards the CXCR3 receptor. Chemical structure of the parent
compound with the MS2 fragmentation scheme is inserted in the figure. I
and II Reconstructed bioaffinity chromatograms after LC separation and
nanofractionation of the metabolic mixture after duplicate injections at two
different concentrations corresponding to 20 and 100 μM pre-incubation
concentration of the parent compound. III Reconstructed bioaffinity
chromatogram after LC separation and nanofractionation of the metabolic
mixture after duplicate injections at the concentration corresponding to
50 μM pre-incubation concentration of the parent compound. Radioligand
binding assay was performed with 125 pM 125I-CXCL10 radioligand. IV
LC-MS traces depicted as extracted ion currents (XICs) of parent
compound (black trace) and formed metabolites (color coded notation).
Correlation between structure identity and bioaffinity is enabled by the
parallel bioaffinity and MS analysis. All bioaffinity chromatograms are
scaled equally and shown as an average of a duplicate measurement, where
the error bars reflect the variation between the two separate measurements
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fragments are shown in Fig. 6. The single charged ion of
Metabolite 3, m/z 622.207, gave three major fragment ions
in the MS2 spectra with m/z 151.088, 268.108, and 418.187,
which indicated oxidation in the pyridyl-methyl moiety. A
closer look at the MS data revealed three small ions corre-
sponding to losses of 18, 17, and 16 Da, which are character-
istic for N-oxides and therefore lead to the conclusion that
Metabolite 3 is the pyridyl-N-oxide of NBI-74330. Metabolite
3 also showed bioaffinity towards CXCR3 (see Fig. 6). These
conclusions are consistent with the findings of Jopling et al.
[32] who used a more elaborate approach to analyze the
bioaffinity of NBI-74330 and its major metabolites. Further-
more, a bioactive pyridyl-N-oxide metabolite is also formed
during metabolism of AMG-487, a structural analog of NBI-
74330. Metabolite 4, m/z 578.181, with a −28 Da shift com-
pared to the parent molecule gave three fragments in MS2
spectra with m/z 135.093, 240.077, and 374.161, indicating
O-deethylation.Metabolite 10,m/z 515.170, showed a −91Da
shift, corresponding toN-dealkylation of the amide and loss of
the pyridinyl-methyl group, which is supported by the frag-
ment ions withm/z 268.108 and 311.151 in its MS2 spectrum.
Metabolic profiling of lead compound VUF11211
In the bioaffinity chromatogram of the metabolic mixture of
VUF11211, three negative peaks were observed which
corresponded to the parent compound and Metabolite 1 and
Metabolite 3 (Fig. 7(I and II)). In addition to this [3H]-
VUF11211 based profiling, for proof of principle, the ability
of metabolites to displace the natural orthosterically binding
chemokine was also demonstrated using a 125I-CXCL10-
based radioligand binding assay. As shown in Fig. 7(III), next
to the parent compound, both metabolites were shown to dis-
place the natural chemokine CXCL10. The developed setup
enabled detection of eight metabolites in the metabolic mix-
ture. All eight metabolites detected were primary
biotransformation products: Metabolites 1–5, which had a
shift of m/z +16 indicating oxidation in the molecule, Metab-
olite 6, which had a shift ofm/z −28 indicating N-deethylation
of the amide, Metabolite 7, which had a shift of m/z −124
pointing at N-dealkylation of the piperidine ring (removal of
4-chloro toluene), Metabolite 8, which had a shift ofm/z −207
that indicated N-dealkylation of the piperazine ring (removal
of 1-(4-chlorobenzyl) piperidine). Metabolites 1 and 3 were
found to have affinity for CXCR3. Structure elucidation of the
VUF11211 metabolites was complicated due to the poor frag-
mentation pattern of the parent compound. VUF11211 gave
only two fragments coming from the same part of the mole-
cule and thus restricted structural information on the rest of the
molecule. At the same time, small changes in the original
structure upon biotransformation yielded completely different
fragmentation patterns for some of the metabolites. Full struc-
ture identification was obtained for Metabolites 6–8, while the
other structures were only partially elucidated. The single-
charge precursor ion [M+H]+ of the parent with m/z
504.229 gives two major fragments in MS2 mode: m/z
125.016 and 208.088, both having a characteristic chlorine
pattern. The proposed structures of these fragments are shown
in Fig. 7, together with the proposed structures of the frag-
ments that were obtained in MS2 spectra of some of the me-
tabolites but not of the parent compound itself. Metabolite 1,
m/z 520.223, had a shift of m/z +16 and gave two major frag-
ments in the MS2 spectra corresponding to ions with m/z
125.016 and 208.089, which indicated oxidation in the ABC
ring of the original molecule (as annotated in Fig. 7
concerning the profile groups in the structure of the com-
pound). Metabolite 2, m/z 520.223, with a shift of m/z +16
compared to the parent compound, gave a fragment with a
mass of m/z 380.220 pointing to oxidation in the benzyl ring
(ring E). The precursor ion of Metabolite 3 with m/z 520.223
gave one fragment in MS2 spectra with m/z 476.192 (loss of
44.031 Da), which led to the conclusion that the oxidation
Table 2 Interpretation of the MS and MS2 results for VUF11211 and its metabolites M1–M8. F1–F5 are characteristic fragments seen in MS2 spectra














Compound Δ Δ Δ Δ Δ Δ
Parent = = = Parent compound, VUF11211
M1 +16 = = +O in ABC
M2 +16 = +O in E
M3 +16 = +O in A
M4 +16 +16 +O in DE
M5 +16 = +O in ABC
M6 −28 = = N-dealkylation of amide (- C2H4 from A)
M7 −124 = = N-dealkylation of piperidine, loss of E
M8 −207 = N-dealkylation of piperazine, loss of DE
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took part on the ethyl moiety of the amide group. Metabolite 4
with m/z 520.219 gave one fragment in MS2 spectra with m/z
224.081, which indicated oxidation in the DE ring, while Me-
tabolite 5 withm/z 520.222 gave a fragment withm/z 208.087
indicating the oxidation to be in the ABC part. Metabolite 6,
m/z 476.198, had a mass shift of −28 Da compared to the
parent compound. Only one fragment ion with m/z 208.092
was found in the MS2 spectra of Metabolite 6.N-Deethylation
of the amide group is proposed to be the metabolic conversion
leading to formation of Metabolite 6. Metabolite 7, m/z
380.221, and Metabolite 8, m/z 297.148, did not give signifi-
cant fragmentation, but the mass shifts of 124 and 207 Da,
respectively, clearly indicated N-dealkylation of the parent
molecule in both cases: Metabolite 7 corresponds to N-
dea lky la t ion of p iper id ine r ing ( remova l o f 4 -
chlorophenylmethyl group) and Metabolite 8 to N-
dealkylation of the piperazine ring (removal of 1-(4-
chlorobenzyl)piperidinyl group).
Discussion
In this paper, a recently developed analytical methodology for
the bioaffinity profiling of mixtures of compounds targeting
the histamine receptor was transferred, optimized, and applied
for bioaffinity assessment of mixture of ligands targeting the
CXCR3 receptor. This method encompasses LC separation of
a mixture of compounds, MS detection, and subsequent struc-
ture elucidation of each compound and a parallel radioligand
binding assay for bioaffinity assessment. Furthermore, the
comprehensive metabolic profiling of the important CXCR3
lead compounds NBI-74330 and VUF11211 with the opti-
mized method is reported. This method allows for efficient
and rapid metabolic profiling of metabolic mixtures of small
ligands towards the CXCR3 chemokine receptor, including
bioaffinity assessment. Successful combination of analytical
techniques and high-resolution at-line nanofractionation with
a CXCR3 radioligand binding assay was demonstrated. This
analytical platform allows for separation of the different com-
pounds in a metabolic mixture and their direct subsequent
bioaffinity analysis. Parallel accurate mass measurements in
MS and MS2 mode allow (partial) structure elucidation of the
formed metabolites with correlation to their bioaffinity. In this
way, metabolic profiling of lead compounds and potential
drug candidates is enabled in a rapid and comprehensive man-
ner. The method provides a quick snapshot of metabolic pro-
files of lead compounds for the CXCR3, including their
bioaffinity, and thereby facilitates this type of profiling earlier
on in drug discovery, to be used for larger sets of interesting
compounds in a drug discovery pipeline.
Metabolic profiling represents a very important step in the
drug discovery process, as this is a first step in the determina-
tion of a pharmacokinetics, bioactivity, and selectivity profile
of a compound. However, due to the need for expensive and
laborious methods, metabolic profiling is generally applied
when a compound is in a more advanced stage of discovery
process. Usually, the metabolic stability is assessed first. At a
later stage, when a lead compound successfully passes meta-
bolic stability tests, the formed metabolites are identified, and
bioactivity and selectivity of metabolites are determined. An
early-stage metabolic (bioactivity) profiling of lead com-
pounds and drug candidates could cut the expenses of devel-
oping a drug by rapid assessment of undesirable metabolic
profiles. New analytical approach allows combining these
analyses in one analytical method and, as such, simultaneous-
ly yields rapid snapshots on metabolic stability and bioaffinity
of the formed metabolites. This was demonstrated on the ex-
ample of two well-known CXCR3 ligands, NBI-74330 and
VUF11211. The new optimizedmethod allowed identification
and (partial) structure elucidation of 9 metabolites of NBI-
74330 and 8 metabolites of VUF1121. These metabolites,
with the exception of the pyridyl N-oxide of NBI-74330, have
not been described previously. Furthermore, metabolite M3 of
NBI-74330 and metabolites M1 and M3 of VUF11211
showed to possess bioaffinity for CXCR3 receptor. However,
the method developed gives only relative estimation of the
binding affinities of the metabolites formed. On the example
of VUF11211 and NBI-74330, it was shown that the method
can detect high affinity binders even if they are present in very
low concentration, close to their IC50 values. Under the con-
ditions used for metabolic incubations in this study, only a
small amount of parent compound (generally 1–5 %) is con-
verted into the metabolites; thus, the concentration of the me-
tabolites in the metabolic mixture is very low. Therefore, it is
estimated that the metabolites that bind to the CXCR3 recep-
tor represent the high affinity binders, such as metabolite M3
of NBI-74330 and metabolites M1 and M3 of VUF11211. All
the other metabolites present could have no affinity for
CXCR3 receptor or they could be low affinity binders. The
real determination of the bioaffinity of each metabolite de-
mands synthesis or purification of the metabolites followed
by determination of their pKi values. A rough estimation of
the Ki value could be made if the metabolite concentrations
are known. A combination of known responses in UVabsorp-
tion and MS ionization efficiency from the mother compound
with the rationale that metabolites with similar structures often
give similar responses can however give an estimate of the
abundance of each metabolite in a mixture, but never absolute
quantification can be done. This rationale together with the
bioaffinity signal is used to depict a metabolite as low-
affinity or high-affinity binder.
At the same time, provided that metabolite elucidation is
sufficiently possible, studying the bioaffinity of the metabo-
lites can give valuable information on affinity hotspots in the
original molecules. In the current paper, this was indicated
with NBI-74330 and VUF11211. For example, the findings
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on NBI-74330 overlap with results found for its analog AMG
487. It entered clinical phase II trials for psoriasis, but was
abandoned due to lack of efficacy, which was attributed to
high variability in drug exposure. Later, metabolic studies of
AMG 487 in healthy volunteers led to the suggestion that
these variations might be due to inhibition of metabolism
caused by formation of O-deethylated AMG 487 and its se-
quential secondary metabolites [21, 22]. The O-deethylated
form of AMG487 (M4) was also found for the closely related
compound NBI-74330 (Fig. 6). In the case of AMG487, this
metabolite was shown to have a lesser ability to displace the
radioligand compared to the parent compound, which pro-
vides a likely explanation for the observation that M4 does
not displace [3H]-VUF11211 in the assay used in this study.
Moreover, another known AMG487 metabolite, a pyridyl N-
oxide, is four times more potent than the parent compound
[36], which is qualitatively in line with the observed displace-
ment of analogous metabolite M3 in Fig. 6. This indeed sug-
gests that M3 binds to the CXCR3 receptor. In this study,
different known metabolites have been found as well, validat-
ing the use of the current method for the screening and char-
acterization of metabolites originating from small-molecule
chemokine receptor ligands.
The approach was also applied to VUF11211, for which, to
date, no metabolites were described in literature. The discov-
ered metabolites provide insight in which parts of the mole-
cule play a role in affinity of the compound for the CXCR3
receptor. For example, the findings of this study underscore
the known importance of the benzyl-piperazine moiety (ED-
part in Fig. 7), as its removal (M8) led to undetectable dis-
placement of [3H]-VUF11211. On the other hand, the metab-
olite M3 showedmaximum radioligand displacement (Fig. 7),
suggesting that oxidized ethyl moieties as amide substituents
may pose a viable strategy. Indeed, such side chains have been
published by the inventors of VUF11211 [26]. As such, the
developed method complements the data obtained through
site-directed mutagenesis and receptor modeling studies and
serves as additional input for medicinal chemistry programs.
Moreover, the presented method would allow for the coupling
of HPLC separation and nanofractionation to, e.g., cyto-
chrome P450 inhibition assays to assess toxicological profiles.
In addition, it was also demonstrated that an analytical ap-
proach as presented in this study can also be used for charac-
terization of chemokine proteins or even derived fragments of
chemokines. Modified chemokines for example appear to act
as antagonists for certain chemokine receptors and may be
valuable as biopharmaceuticals.
Altogether, the analytical techniques described in this study
efficiently combine metabolic profiling and chemokine recep-
tor ligand binding assays using nanofractionation as a linking
technology. Moreover, the developed method allows the iden-
tification of liable hotspots in lead compounds. Hence, such
combined approach allows implementation of comprehensive
metabolic profiling and directs lead optimization of drug can-
didates in an early phase of the drug discovery process.
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